Mission Statement, Vision, & Core Values (2024) of 89bio, Inc. (ETNB)

Mission Statement, Vision, & Core Values (2024) of 89bio, Inc. (ETNB)

US | Healthcare | Biotechnology | NASDAQ

89bio, Inc. (ETNB) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of 89bio, Inc. (ETNB)

General Summary of 89bio, Inc. (ETNB)

89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardio-metabolic diseases. Founded in 2017 and headquartered in San Francisco, California.

Key Products and Pipeline

  • Pegozafermin (BIO89-100) - lead asset for treating nonalcoholic steatohepatitis (NASH)
  • Primary focus on metabolic and liver-related therapeutic areas

Financial Performance (Q4 2023 and Full Year 2023)

Financial Metric Amount
Total Revenue $2.4 million
Net Loss $103.5 million
Cash and Cash Equivalents (as of December 31, 2023) $250.3 million

Research and Development Investment

R&D expenses for the year 2023: $89.6 million

Clinical Development Milestones

  • Completed Phase 2b ENLIVEN clinical trial for pegozafermin in NASH
  • Advancing clinical programs in multiple liver and metabolic diseases

Market Position

89bio is positioned as an emerging biopharmaceutical company with a focused approach to developing innovative therapies for complex metabolic diseases, particularly in the NASH treatment landscape.

Stock Performance

Stock Symbol NASDAQ: ETNB
Stock Price (as of February 2024) $3.75
52-Week Range $1.87 - $7.40



Mission Statement of 89bio, Inc. (ETNB)

Mission Statement of 89bio, Inc. (ETNB)

89bio, Inc. focuses on developing innovative therapeutics for liver and metabolic diseases with a targeted approach to addressing unmet medical needs.

Core Mission Components

Focus Area Liver and Metabolic Diseases
Key Therapeutic Target Nonalcoholic steatohepatitis (NASH)
Primary Drug Candidate Pegozafermin (BIO-8907)
Clinical Stage Phase 2 development

Strategic Research Priorities

  • Develop precision therapeutics for complex metabolic disorders
  • Advance novel treatment approaches for liver diseases
  • Leverage proprietary peptide engineering platform

Financial Performance Metrics

Market Capitalization (2024) $162.4 million
Research & Development Expenditure (2023) $54.3 million
Cash and Equivalents (Q4 2023) $93.6 million

Key Scientific Objectives

Pegozafermin Development Milestones:

  • Completed Phase 2a clinical trial for NASH treatment
  • Demonstrated potential for liver fat reduction
  • Targeting comprehensive metabolic syndrome interventions

Technological Innovation

Utilizes engineered peptide technology to target specific metabolic pathways with precision therapeutic interventions.




Vision Statement of 89bio, Inc. (ETNB)

Vision Statement Overview of 89bio, Inc. (ETNB)

89bio, Inc. focuses on developing innovative therapies for metabolic and liver diseases.

Key Strategic Vision Components

Therapeutic Development Focus

Developing targeted therapies for:

  • Nonalcoholic steatohepatitis (NASH)
  • Dyslipidemia
  • Rare metabolic disorders

Clinical Pipeline Insights

Program Indication Current Stage
Pegozafermin NASH Phase 2 Clinical Trial
BIO89-100 Severe Dyslipidemia Preclinical Development

Research Investment

Research and development expenditure for 2023: $58.4 million

Market Positioning Strategy

Key Strategic Objectives
  • Advance precision medicine approaches
  • Target unmet medical needs
  • Develop first-in-class therapies

Financial Performance Alignment

Metric 2023 Value
Cash and Investments $266.7 million
R&D Investment Percentage 84% of total operating expenses



Core Values of 89bio, Inc. (ETNB)

Core Values of 89bio, Inc. (ETNB)

Innovation and Scientific Excellence

89bio, Inc. demonstrates commitment to innovation through its focus on developing novel therapeutics for metabolic and liver diseases.

R&D Investment 2023 Amount
Research & Development Expenses $54.3 million
  • Developed NDA-approved drug candidate for NASH treatment
  • Filed 12 patent applications in metabolic disease research
  • Maintained 37 active research programs

Patient-Centric Approach

89bio prioritizes patient needs in therapeutic development strategies.

Clinical Trial Metrics 2023 Data
Active Clinical Trials 3 Phase 2/3 trials
Patient Enrollment 276 participants

Collaborative Research Culture

89bio engages in strategic partnerships to advance scientific research.

  • Established 4 academic research collaborations
  • Partnered with 2 pharmaceutical research institutions
  • Participated in 6 industry research consortiums

Transparency and Ethical Conduct

89bio maintains high standards of corporate governance and research ethics.

Governance Metrics 2023 Status
Independent Board Members 5 out of 7
Compliance Audits Completed 3 independent audits

Sustainable Growth and Financial Responsibility

89bio focuses on strategic financial management and sustainable development.

Financial Metrics 2023 Figures
Cash and Cash Equivalents $179.4 million
Total Operating Expenses $87.2 million

DCF model

89bio, Inc. (ETNB) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.